Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape.

Shooshani T, Cherupalla B, Durand A, Aung MH

Open source

DOI
10.3390/ijms27209071
Published
2026 Oct 13
Container
International journal of molecular sciences
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ijms27209071,
  title = {Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape.},
  author = {Shooshani T and Cherupalla B and Durand A and Aung MH},
  year = {2026},
  journal = {International journal of molecular sciences},
  doi = {10.3390/ijms27209071},
  url = {https://doi.org/10.3390/ijms27209071}
}

RIS

TY  - JOUR
TI  - Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape.
AU  - Shooshani T
AU  - Cherupalla B
AU  - Durand A
AU  - Aung MH
PY  - 2026
JO  - International journal of molecular sciences
DO  - 10.3390/ijms27209071
UR  - https://doi.org/10.3390/ijms27209071
ER  - 

APA

T, S., B, C., A, D., & MH, A. (2026). Thyroid Eye Disease in the Teprotumumab Era: Pathophysiology, Clinical Activity Assessment, and an Updated Therapeutic Landscape.. International journal of molecular sciences. https://doi.org/10.3390/ijms27209071

Source records